Pharma in Focus
Email Address Sign-Up

Australia's most trusted source of pharma news

Buy now fake rolex


Gilead boss cops huge pay cut

Posted 7 April 2021 AM

After a triumphant year pulling off two big acquisitions, repurposing remdesivir as a treatment for Covid patients plus overseeing growth in HIV products despite a patent expiration, Gilead Sciences CEO Daniel O'Day has had his annual pay cheque slashed by 35 per cent.

While O'Day's total pay package was a still sizeable $US19 million it dropped significantly from $US29.1 million a year earlier.

Looks like you've lost your access to Pharma in Focus. To restore access or update your subscription, click here

Top of the Hill
All fine, nothing to see here
How politics made a mess of the rollout
Special Report
PBAC July Agenda
Committee to assess 36 submissions
Approvals Action
First copy of gout drug
Plus new formulations of PBS-listed drugs
Special Report
Aust Covid Vaccine Tracker
UPDATE: Distribution of two mRNA vaccines overseas